Autoimmune Encephalitis in Children: An Update

被引:18
|
作者
Garg, Divyani [1 ]
Mohammad, Shekeeb S. [3 ,4 ]
Sharma, Suvasini [2 ]
机构
[1] Lady Hardinge Med Coll & Hosp, Dept Neurol, New Delhi, India
[2] Lady Hardinge Med Coll & Hosp, Dept Pediat, Div Neurol, New Delhi, India
[3] Childrens Hosp Westmead, Dept Neurol, Movement Disorder Clin, Sydney, NSW, Australia
[4] Childrens Hosp Westmead, USyd Clin Sch, Sydney, NSW, Australia
关键词
Anti-NMDAR encephalitis; Autoimmune epilepsy; Limbic encephalitis; Movement disorders; D-ASPARTATE RECEPTOR; HERPES-SIMPLEX ENCEPHALITIS; LIMBIC ENCEPHALITIS; ANTIBODY ENCEPHALITIS; NMDAR ENCEPHALITIS; MRI FINDINGS; CASE SERIES; FOLLOW-UP; DIAGNOSIS; PREVALENCE;
D O I
10.1007/s13312-020-1896-5
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Context Autoimmune encephalitis has acquired immense significance as a treatable cause of encephalopathy, epilepsy and movement disorders in children. In this review, we discuss the various clinical syndromes, diagnosis, treatment and prognosis in children. Evidence acquisition A MEDLINE search strategy using the following terms (1998-2019) was adopted for this review. Limits of 'Human' and 'English' were applied. Search terms included: "autoimmune encephalitis", "autoimmune encephalitis AND epidemiology", "pathophysiology", "diagnosis" and "treatment" for studies in children. Review articles, practice parameters, guidelines, systematic reviews, meta-analyses, randomized controlled trials, cohort studies, case series and case reports were included. Conclusions Autoimmune encephalitis is being increasingly recognized in children. Anti-NMDAR encephalitis is the most common form. Children present with a polysymptomatic presentation including behavioral changes, psychosis, sleep disturbances, mutism, seizures, movement disorders, memory impairment as well as other neurocognitive deficits. Diagnosis is based on suggestive history and ancillary investigations including magnetic resonance imaging, cerebrospinal fluid analysis, and serology for autoantibodies. Treatment is based on immunomodulation of the acute episode followed by maintenance therapy, with earlier initiation being associated with better outcomes. Prognosis depends on the type of clinical syndrome.
引用
收藏
页码:662 / 670
页数:9
相关论文
共 50 条
  • [1] Autoimmune Encephalitis in Children: An Update
    Divyani Garg
    Shekeeb S. Mohammad
    Suvasini Sharma
    Indian Pediatrics, 2020, 57 : 662 - 670
  • [2] Autoimmune encephalitis update
    Dalmau, Josep
    Rosenfeld, Myrna R.
    NEURO-ONCOLOGY, 2014, 16 (06) : 771 - 778
  • [3] Autoimmune Encephalitis in Children
    Hardy, Duriel
    PEDIATRIC NEUROLOGY, 2022, 132 : 56 - 66
  • [4] Movement disorders in autoimmune encephalitis: an update
    Qin, Mengting
    Chen, Jiaojiao
    Guo, Xiaoqing
    Xiang, Xuying
    Nie, Lei
    Wang, Yong
    Mao, Ling
    JOURNAL OF NEUROLOGY, 2023, 270 (11) : 5288 - 5302
  • [5] Autoimmune Encephalitis
    Jafarpour, Saba
    Santoro, Jonathan D.
    PEDIATRICS IN REVIEW, 2022, 43 (04) : 198 - 211
  • [6] Update on the diagnosis and management of autoimmune encephalitis
    Ellul, Mark A.
    Wood, Greta
    Van den Tooren, Harriet
    Easton, Ava
    Babu, Ashik
    Michael, Benedict D.
    CLINICAL MEDICINE, 2020, 20 (04) : 389 - 392
  • [7] Treatment strategies for autoimmune encephalitis
    Shin, Yong-Won
    Lee, Soon-Tae
    Park, Kyung-Il
    Jung, Keun-Hwa
    Jung, Ki-Young
    Lee, Sang Kun
    Chu, Kon
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2017, 11 : 1 - 19
  • [8] The Diagnosis and Treatment of Autoimmune Encephalitis
    Lancaster, Eric
    JOURNAL OF CLINICAL NEUROLOGY, 2016, 12 (01): : 1 - 13
  • [9] Autoimmune encephalitis
    Newman, M. P.
    Blum, S.
    Wong, R. C. W.
    Scott, J. G.
    Prain, K.
    Wilson, R. J.
    Gillis, D.
    INTERNAL MEDICINE JOURNAL, 2016, 46 (02) : 148 - 157
  • [10] Autoimmune Encephalitis: Current Knowledge on Subtypes, Disease Mechanisms and Treatment
    Nissen, Mette Scheller
    Ryding, Matias
    Meyer, Morten
    Blaabjerg, Morten
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2020, 19 (08) : 584 - 598